Improvement of visual acuity in patients with severe visual loss affected by multiple sclerosis treated with natalizumab: A case report

Neurological Sciences

Volumn 31, Issue SUPPL. 3, 2010, Pages

  Florio, Ciro ^a   Maniscalco, Giorgia Teresa ^a  

^a Multiple Sclerosis Regional Center A Cardarelli   (Italy)

Author keywords

Multiple sclerosis; Natalizumab

Indexed keywords

MONOCLONAL ANTIBODY; NATALIZUMAB;

ADULT; CASE REPORT; FEMALE; HOSPITALIZATION; HUMAN; IMMUNOLOGY; MULTIPLE SCLEROSIS; REVIEW; TREATMENT OUTCOME; VISUAL ACUITY; VISUAL DISORDER;

ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; HUMANS; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; VISION, LOW; VISUAL ACUITY; YOUNG ADULT;

EID: 84856374280     PISSN: 15901874     EISSN: 15903478     Source Type: Journal    
DOI: 10.1007/s10072-010-0349-7     Document Type: Conference Paper

References (5)

1. The PRISMS (Preventions of relapses, Disability by Interferon beta1-a Subcutaneously in Multiple Sclerosis) Study Group (1998) Randomized double-blind, placebo-controlled study of interferon beta1-a in relapsing-remitting multiple sclerosis. Lancet 352:1498-1504
2. The IFNB Study Group (1993) Interferon beta1-b is effective in relapsing-remitting multiple sclerosis. Clinical results of a multicenter, randomized, double-blind placebo-controlled trial. Neurology 43:655-661
3. Johnson KP et al (1995) Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trail. Neurology 45:1268-1276
4. Polman CH et al (2006) A randomized placebo-controlled trial of natalizumab for relapsing-remitting multiple sclerosis; AFFIRM. N Engl J Med 354:899-910
5. Richard A et al (2006) Natalizumab plus interferon beta1-a for relapsing-remitting multiple sclerosis; SENTINEL. N Engl J Med 354:911-923